Results 21 to 30 of about 60,513 (321)

VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis

TH Open, 2021
Background Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor A (VEGFA) are associated with susceptibility to several diseases including cancer.
Laura Villani, Vittorio Rosti, Margherita Massa, Rita Campanelli, Paolo Catarsi, Adriana Carolei, Carlotta Abbà, Annalisa de Silvstri, Robert Peter Gale, Giovanni Barosi   +9 more
doaj   +1 more source

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Blood Advances, 2022
Key Points RUX dose, spleen response, and transfusion requirement in the first 6 months of RUX treatment predict overall survival in MF. The RR6 model overcomes conventional risk stratification in RUX-treated MF.
M. Maffioli, B. Mora, S. Ball, A. Iurlo, E. Elli, M. Finazzi, N. Polverelli, E. Rumi, M. Caramella, M. Carraro, M. D'adda, A. Molteni, C. Sissa, F. Lunghi, A. Vismara, M. Ubezio, A. Guidetti, S. Caberlon, M. Anghilieri, R. Komrokji, D. Cattaneo, M. D. Della Porta, T. Giorgino, L. Bertù, M. Brociner, A. Kuykendall, F. Passamonti   +26 more
semanticscholar   +1 more source

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm

Nature Communications, 2022
Interleukin-1β (IL-1β) is a master regulator of inflammation. Increased activity of IL-1β has been implicated in various pathological conditions including myeloproliferative neoplasms (MPNs).
S. Rai, Élodie Grockowiak, N. Hansen, Damien Luque Paz, Cédric B. Stoll, Hao Hui, Gabriele Mild-Schneider, S. Dirnhofer, C. Farady, S. Méndez-Ferrer, R. Skoda   +10 more
semanticscholar   +1 more source

Defining disease modification in myelofibrosis in the era of targeted therapy

Cancer, 2022
The development of targeted therapies for the treatment of myelofibrosis highlights a unique issue in a field that has historically relied on symptom relief, rather than survival benefit or modification of disease course, as key response criteria.
N. Pemmaraju, S. Verstovsek, Ruben A. Mesa, Vikas Gupta, Jacqueline S. Garcia, J. Scandura, S. Oh, F. Passamonti, K. Döhner, A. Mead   +9 more
semanticscholar   +1 more source

Biological drivers of clinical phenotype in myelofibrosis

Leukemia, 2022
Myelofibrosis (MF) is a myeloproliferative disorder that exhibits considerable biological and clinical heterogeneity. At the two ends of the disease spectrum are the myelodepletive or cytopenic phenotype and the myeloproliferative phenotype.
J. Mascarenhas, H. Gleitz, H. Chifotides, C. Harrison, S. Verstovsek, A. Vannucchi, R. Rampal, J. Kiladjian, W. Vainchenker, R. Hoffman, R. Schneider, A. List   +11 more
semanticscholar   +1 more source

Correction to "Novel approaches in myelofibrosis". [PDF]

Hemasphere
HemaSphere, Volume 9, Issue 10, October 2025.
europepmc   +2 more sources

Improved survival of patients with myelofibrosis in the last decade: Single‐center experience

Cancer, 2022
The management of myelofibrosis (MF) has changed over the last several years and could have an impact on patient outcome. This study evaluates the survival of patients with MF at the authors' institution to determine whether it changed in the last decade.
L. Masarova, P. Bose, N. Pemmaraju, N. Daver, K. Sasaki, H. Chifotides, Lingsha Zhou, H. Kantarjian, Z. Estrov, S. Verstovsek   +9 more
semanticscholar   +1 more source

The Role of Navitoclax in Myelofibrosis [PDF]

Cureus, 2021
Primary myelofibrosis (PMF) is the most aggressive type of chronic myeloproliferative neoplasm, characterized by a disarray of hematopoietic stem cells and bone marrow fibrosis. The estimated incidence is 1.5 per 100,000 individuals per year with a median survival of less than six years.
Pandravada, Sasirekha, Sandler, Steven
openaire   +4 more sources

Targeted sequencing of candidate gene regions for myelofibrosis in dogs

Journal of Veterinary Internal Medicine, 2022
Background Myelofibrosis often lacks an identifiable cause in dogs. In humans, most primary myelofibrosis cases develop secondary to driver mutations in JAK2, CALR, or MPL.
Amelia G. Campbell, Davis M. Seelig, Joan D. Beckman, Katie M. Minor, Daniel A. Heinrich, Steven G. Friedenberg, Jaime F. Modiano, Eva Furrow   +7 more
doaj   +1 more source

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression

Frontiers in Oncology, 2022
In primary myelofibrosis, extra-domain A fibronectin (EDA-FN), the result of alternative splicing of FN gene, sustains megakaryocyte proliferation and confers a pro-inflammatory phenotype to bone marrow cell niches. In this work we assessed the levels of
Alessandro Malara, Cristian Gruppi, Margherita Massa, Maria Enrica Tira, Vittorio Rosti, Alessandra Balduini, Giovanni Barosi   +6 more
doaj   +1 more source